发明名称 Triazole compounds useful as protein kinase inhibitors
摘要 This invention describes novel triazole compounds of formula IX: wherein Z<SUP>1 </SUP>is nitrogen or CR<SUP>9 </SUP>and Z<SUP>2 </SUP>is nitrogen or CH, provided that at least one of Z<SUP>1 </SUP>and Z<SUP>2 </SUP>is nitrogen; G is Ring C or Ring D; Ring C is selected from a phenyl, pyridinyl, pyrimidinyl, pyridazinyl, pyrazinyl, or 1,2,4-triazinyl ring, wherein said Ring C has one or two ortho substituents independently selected from -R<SUP>1</SUP>; Ring D is a 5-7 membered monocyclic ring or 8-10 membered bicyclic ring selected from aryl, heteroaryl, heterocyclyl or carbocyclyl; R<SUP>x </SUP>and R<SUP>y </SUP>are independently selected from T-R<SUP>3</SUP>, or R<SUP>x </SUP>and R<SUP>y </SUP>are taken together with their intervening atoms to form a fused ring; R<SUP>1</SUP>, R<SUP>3</SUP>, and T are as described in the specification. The compounds are useful as protein kinase inhibitors, especially as inhibitors of GSK-3 and Aurora, for treating diseases such as diabetes, cancer, and Alzheimer's disease.
申请公布号 US7115739(B2) 申请公布日期 2006.10.03
申请号 US20010953471 申请日期 2001.09.14
申请人 VERTEX PHARMACEUTICALS INCORPORATED 发明人 BEBBINGTON DAVID;KNEGTEL RONALD;BINCH HAYLEY;GOLEC JULIAN M. C.;LI PAN;CHARIER JEAN-DAMIEN
分类号 C07D403/12;A61K31/415;A61K31/437;A61K31/4709;A61K31/4725;A61K31/501;A61K31/5025;A61K31/506;A61K31/517;A61K31/519;A61K31/52;A61K31/53;A61K31/5377;A61K31/541;A61K31/55;A61K45/00;A61P1/16;A61P3/08;A61P3/10;A61P3/14;A61P5/00;A61P5/48;A61P9/00;A61P9/10;A61P11/06;A61P17/06;A61P19/00;A61P19/02;A61P19/10;A61P25/18;A61P25/28;A61P29/00;A61P31/12;A61P35/00;A61P35/02;A61P37/02;A61P37/06;A61P37/08;A61P43/00;C07D239/26;C07D239/36;C07D239/70;C07D239/88;C07D401/12;C07D401/14;C07D403/14;C07D405/14;C07D407/14;C07D409/14;C07D413/14;C07D417/14;C07D471/04;C07D473/16;C07D475/10;C07D487/04;C07D491/04;C07D491/044;C07D491/048;C07D491/052;C07D491/107;C07D491/113;C07D491/20;C07D493/04;C07D495/04;C07D498/04;C07D513/04;C07D521/00 主分类号 C07D403/12
代理机构 代理人
主权项
地址